5471-77-2

Basic information

• Product Name: 3-Ethoxy-2,2-dimethyl-3-oxopropanoic acid
• Synonyms: 3-Ethoxy-2,2-dimethyl-3-oxopropanoic acid-13;NSC 28452;3-Ethoxy-2,2-dimethyl-3-oxopropanoic acid;3-ethoxy-3-keto-2,2-dimethyl-propionic acid;DiMethylMalonic Acid Monoethyl Ester
• CAS NO: 5471-77-2
• Molecular Formula: C₇H₁₂O₄
• Molecular Weight: 160.17
• Mol File: 5471-77-2.mol
• Article Data: 14

Chemical Properties

• Boiling Point: 250.5 °C at 760 mmHg
• Flash Point: 97.7 °C
• Appearance: /
• Density: 1.126 g/cm³
• Vapor Pressure: 0.00684mmHg at 25°C
• Refractive Index: 1.444
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 3.00±0.36(Predicted)
• CAS DataBase Reference: 3-Ethoxy-2,2-dimethyl-3-oxopropanoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Ethoxy-2,2-dimethyl-3-oxopropanoic acid(5471-77-2)
• EPA Substance Registry System: 3-Ethoxy-2,2-dimethyl-3-oxopropanoic acid(5471-77-2)

Safety Data

• Hazardous Substances Data: 5471-77-2(Hazardous Substances Data)

Usage

Synthesis Reference(s)

Tetrahedron Letters, 15, p. 2721, 1974 DOI: 10.1016/S0040-4039(01)91723-X

InChI:InChI=1/C7H12O4/c1-4-11-6(10)7(2,3)5(8)9/h4H2,1-3H3,(H,8,9)

Upstream product

• 1619-62-1 2,2-dimethylmalonic acid diethyl ester 
• 3495-36-1 cesium formate 
• 97-63-2 methyl methacrylate 
• 801301-34-8 2-dimethylstibanyl-2-methylpropionic acid ethyl ester 
• 124-38-9 carbon dioxide 
• 14002-73-4 3-hydroxy-2,2-dimethyl-propionic acid ethyl ester 
• 97-62-1 Ethyl isobutyrate 
• 541-41-3 chloroformic acid ethyl ester 
• 79-31-2 isobutyric Acid 

Downstream Products

• 342797-12-0 (3R)-3,7,7-trimethyl-3-phenylpyrrolo[2,1-c][1,4]oxazine-1,4,6,8-tetraone 
• 342797-11-9 ethyl (2'R)-2,2-dimethyl-3-(2'-methyl-3',6'-dioxo-2'-phenylmorpholin-4'-yl)-3-oxopropionate 
• 342797-13-1 (3R,8aR)-8a-hydroxymethyl-3,7,7-trimethyl-3-phenylpyrrolo[2,1-c][1,4]oxazine-1,4,6,8-tetraone 
• 342797-16-4 (3R,8S,8aR)-8-Hydroxy-8a-hydroxymethyl-3,7,7-trimethyl-3-phenyl-dihydro-pyrrolo[2,1-c][1,4]oxazine-1,4,6-trione 
• 50-29-3 p,p'-DDT 
• 1415547-06-6 N₁-((S)-1-(4-(hex-5-enyloxy)phenyl)-2-hydroxyethyl)-N₃-((R)-1-hydroxy-3-(4-(undec-10-enyloxy)phenyl)propan-2-yl)-2,2-dimethylmalonamide 
• 1415547-15-7 (S)-3-(1-(4-(hex-5-enyloxy)phenyl)-2-hydroxyethylamino)-2,2-dimethyl-3-oxopropanoic acid 

Relevant articles and documents

Oxadiazole and thiadiazole compounds and preparation methods and applications thereof

The invention discloses oxadiazole and thiadiazole compoundsand preparation methods and applications thereof.The compounds is shown as a formula I or a formula II.The oxadiazole or thiadiazole compound or a pharmaceutically acceptable salt, racemate, opti

Discovery of potent c-MET inhibitors with new scaffold having different quinazoline, pyridine and tetrahydro-pyridothienopyrimidine headgroups

Cellular mesenchymal-epithelial transition factor (c-MET) is closely linked to human malignancies, which makes it an important target for treatment of cancer. In this study, a series of 3-methoxy-N-phenylbenzamide derivatives, N-(3-(tert-butyl)-1-phenyl-1H-pyrazol-5-yl) benzamide derivatives and N1-(3-fluoro-4-methoxyphenyl)-N3-(4-fluorophenyl) malonamide derivatives were designed and synthesized, some of them were identified as c-MET inhibitors. Among these compounds with new scaffolds having different quinazoline, pyridine and tetrahydro-pyridothienopyrimidine head groups, compound 11c, 11i, 13b, 13h exhibited both potent inhibitory activities against c-MET and high anticancer activity against tested cancer cell lines in vitro. In addition, kinase selectivity assay further demonstrated that both 13b and 13h are potent and selective c-MET inhibitors. Molecular docking supported that they bound well to c-MET and VEGFR2, which demonstrates that they are potential c-MET RTK inhibitors for cancer therapy.

PEPTIDOMIMETIC COMPOUNDS AND ANTIBODY-DRUG CONJUGATES THEREOF

This invention relates to peptidomimetic linkers and anti-body drug conjugates thereof, to pharmaceutical compositions containing them, and to their use in therapy for the prevention or treatment of cancer.